The earnings of S&P 500 constituents grew by 31% year-on-year in the second quarter, exceeding the expected 23%, marking the strongest increase since 1992. Over 90% of the constituents have reported their earnings, and the overall performance in the first half of the year is expected to be the best since 2021. Analysts point out that the earnings beat expectations due to the resilience of the U.S. economy and the profit margin improvements brought by AI, with net profit margins rising from 14% to nearly 16%. Mark Hackett, Chief Market Strategist at Nationwide, stated that AI has transformed into a profit center this year. The S&P 500's price-to-earnings ratio for the next 12 months has decreased from about 26 times at the beginning of the year to just below 22 times, and Wall Street strategists have raised the year-end target to 7894 points, indicating about a 1% upside from historical highs. The full-year earnings growth expectation has been revised up from 15% at the beginning of the year to 27%. This round of earnings growth is no longer limited to large tech companies, as about three-quarters of the companies that have disclosed their performance achieved earnings per share and revenue above expectations, with healthcare being the only sector experiencing a contraction in profits.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.



Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.












Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.